The IMPA1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the IMPA1 gene in the HAP1 cell line. This loss-of-function model targets IMPA1, which encodes inositol monophosphatase, a critical enzyme in the phosphatidylinositol signaling cycle. The polyclonal format provides a heterogeneous knockout population, offering a robust system for studying gene function without the need for single-cell cloning, and is well-suited for pooled functional assays and large-scale genetic screens. The cells are supplied as a ready-to-use research tool, enabling direct interrogation of IMPA1-dependent processes.
The HAP1 host cell line is a human chronic myelogenous leukemia (CML) cell line with a near-haploid karyotype, derived from a male donor and characterized by BCR-ABL1 positivity. HAP1 cells grow adherently and display hematopoietic progenitor-like properties, making them an attractive model for hematopoietic and cancer research. The near-haploid nature significantly simplifies genetic manipulation and loss-of-function studies, as it reduces gene redundancy and facilitates the generation of clean knockout models. This genetic background is especially valuable for drug target validation, synthetic lethality screens, and pathway dissection in a human cancer context.
IMPA1 functions as a magnesium-dependent inositol monophosphatase that hydrolyzes inositol monophosphates to release free inositol and inorganic phosphate, a rate-limiting step in the recycling of inositol for phosphatidylinositol (PI) resynthesis. This enzyme operates downstream of G protein-coupled receptors (GPCRs) and growth factor receptors that activate phospholipase C (PLC), leading to the generation of IP3 and DAG; subsequent IP3 dephosphorylation yields inositol monophosphates, which are substrates for IMPA1. IMPA1 is directly inhibited by lithium ions, an uncompetitive inhibitor, and its activity is also regulated by PKC and upstream signaling cascades. The regenerated inositol feeds back into the PI cycle, supporting PIP2 synthesis, PKC activation, and calcium mobilization. Indirectly, IMPA1 influences GSK3?? activity through inositol availability, linking it to the Wnt signaling pathway. Interacting factors include its substrate inositol monophosphates and the related phosphatase INPP5E.
In the context of HAP1 cells, IMPA1 knockout creates a model to investigate inositol depletion phenotypes and the cellular consequences of disrupted phosphatidylinositol signaling. The near-haploid background reduces genetic buffering, potentially sensitizing cells to alterations in inositol metabolism and revealing phenotypes that might be masked in diploid lines. This system is particularly relevant for studying bipolar disorder and lithium responsiveness, as IMPA1 is a central target of lithium therapy. Additionally, the model can be used to explore neurodevelopmental disorders and cancer dependencies linked to PI signaling, given HAP1’s leukemic origin. The absence of IMPA1 allows researchers to dissect the direct and indirect effects of inositol monophosphatase loss on downstream targets such as GSK3??, PKC, and calcium flux, providing a clean background for mechanistic studies.
This IMPA1 knockout cell population is designed for a variety of research applications, including target validation for bipolar disorder therapeutics, elucidation of lithium’s mechanism of action, dissection of the phosphatidylinositol signaling system, and investigation of GPCR-mediated signaling regulation. Researchers can employ representative assays such as Western blotting to confirm IMPA1 ablation, inositol phosphate accumulation measurements, cell viability assays under lithium or inositol-depleted conditions, phospho-GSK3?? analysis, phosphatidylinositol profiling by mass spectrometry, calcium flux measurements, and quantitative real-time PCR for pathway components. The cells are also amenable to proliferation assays and synthetic lethality screens in the context of cancer. For further technical specifications, pricing, or collaborative projects, please contact Ascent Research.
